Artivion, Inc. (NYSE:AORT) Given Average Rating of "Moderate Buy" by Analysts

Key Points

• Analysts rate Artivion “Moderate Buy”: seven of eight analysts recommend buying the stock, with one sell rating and an average 12-month price target of $44.83.
• Artivion reported quarterly EPS of $0.13 and revenue of $125.76 million, exceeding analysts’ revenue estimate of $119.99 million. Shares opened at $23.38, near the lower end of their 52-week range.
• Insiders sold 90,460 shares worth approximately $2.56 million over the past 90 days, while institutional investors own 86.37% of the company.

Artivion, Inc. (NYSE:AORT - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight brokerages that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and seven have issued a buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $44.8333.

AORT has been the topic of several recent analyst reports. Weiss Ratings cut shares of Artivion from a "sell (d+)" rating to a "sell (d-)" rating in a research note on Tuesday, August 11th. Citigroup reaffirmed a "market outperform" rating on shares of Artivion in a report on Tuesday, July 21st. Wall Street Zen downgraded Artivion from a "hold" rating to a "sell" rating in a research report on Saturday, August 15th. Canaccord Genuity Group lifted their price objective on Artivion from $39.00 to $40.00 and gave the company a "buy" rating in a research note on Tuesday, August 18th. Finally, Stifel Nicolaus set a $45.00 target price on Artivion in a research report on Monday, June 1st.

Insider Activity

In related news, SVP Jean F. Holloway sold 977 shares of the company's stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $28.49, for a total value of $27,834.73. Following the transaction, the senior vice president directly owned 184,118 shares in the company, valued at approximately $5,245,521.82. This represents a 0.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO James P. Mackin sold 70,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total transaction of $2,026,500.00. Following the completion of the sale, the chief executive officer directly owned 877,275 shares in the company, valued at $25,397,111.25. This represents a 7.39% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 90,460 shares of company stock worth $2,557,366. 6.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Artivion

Institutional investors have recently made changes to their positions in the stock. Rockefeller Capital Management L.P. lifted its holdings in shares of Artivion by 150.0% during the 4th quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company's stock worth $30,000 after acquiring an additional 399 shares during the last quarter. Larson Financial Group LLC grew its position in Artivion by 148.5% in the fourth quarter. Larson Financial Group LLC now owns 942 shares of the company's stock worth $43,000 after acquiring an additional 563 shares in the last quarter. Quantbot Technologies LP bought a new position in Artivion in the second quarter valued at $103,000. Pictet Asset Management Holding SA increased its stake in Artivion by 25.6% in the first quarter. Pictet Asset Management Holding SA now owns 5,520 shares of the company's stock valued at $202,000 after acquiring an additional 1,125 shares during the last quarter. Finally, Commerce Bank purchased a new stake in Artivion during the second quarter valued at about $208,000. Institutional investors own 86.37% of the company's stock.

Artivion Trading Down 2.1%

Shares of AORT opened at $23.38 on Friday. Artivion has a twelve month low of $19.16 and a twelve month high of $48.25. The stock has a market cap of $1.14 billion, a PE ratio of -333.94 and a beta of 1.25. The company has a quick ratio of 2.51, a current ratio of 3.47 and a debt-to-equity ratio of 0.82. The business's 50-day moving average price is $26.30 and its 200-day moving average price is $28.35.

Artivion (NYSE:AORT - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The company had revenue of $125.76 million during the quarter, compared to analyst estimates of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, equities analysts forecast that Artivion will post 0.45 EPS for the current fiscal year.

About Artivion

Artivion, Inc is a medical device company focused on developing and supplying products used in cardiac and vascular surgery. The company's portfolio includes implantable devices, surgical products and preservation technologies designed to treat diseases of the heart and aorta.

Its products include the On-X mechanical heart valve, aortic stent grafts and surgical grafts, as well as BioGlue Surgical Adhesive and other products used to control bleeding and reinforce tissue during cardiovascular procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.